http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2463868-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fa9a2244bcefb810096034dd8bb5827 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-453 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4453 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 1999-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f34fee6d9a1881f588f48b010903edbc |
| publicationDate | 2014-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2463868-T3 |
| titleOfInvention | Selective estrogen receptor modulator in combination with dehydroepiandrosterone (DHEA) or the like |
| abstract | Composition for use as a medicament in a combination therapy to treat or reduce the risk of contracting a disorder selected from the group consisting of breast cancer, endometrial cancer, uterine cancer and ovarian cancer, the composition comprising: a) a Sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-eno-3β, 17β-diol, 4-androstene-3, 17-dione and a prodrug that becomes in vivo in any of the above sex steroid precursors and b) a therapeutically effective amount of a selective estrogen receptor modulator that is a benzopyran derivative, wherein the prodrug converted in vivo into a sex steroid precursor has the general formula: wherein X is selected from the group consisting of H-, ROC-, RCO2CHRa- and RbSO2- (R being selected from the group consisting of hydrogen, C1-C18 alkyl) al or branched, straight or branched chain (C2-C18) alkenyl, straight or branched chain (C2-C18) alkynyl, aryl, furyl, straight or branched chain (C1-C18) alkoxy, (C2-C18) alkenyloxy straight or branched chain, straight or branched (C2-C18) alkynyloxy, aryloxy, furyloxy and halogen or carboxyl analogs of the foregoing; Ra being hydrogen or (C1-C6) alkyl and Rb being selected from the group consisting of hydroxyl (or salts thereof), methyl, phenyl and p-toluyl); in which Y is the carbonyl oxygen or Y represents a β-OX (having X the same meaning as above) and α-H and in which the selective estrogen receptor modulator has the following formula: in which R1 and R2 are independently hydrogen, hydroxyl or a moiety that is converted to hydroxyl in vivo; in which Z is a remainder of bivalent closure; in which R10 is a bivalent moiety that separates L from ring B by 4-10 intervening atoms; where L is a bivalent or trivalent polar moiety selected from the group -SO-, -CON-, -N <and - SON <; wherein G1 is selected from the group consisting of hydrogen, a C1 to C5 hydrocarbon or a bivalent moiety linking G2 with L to form a 5- to 7-membered heterocyclic ring and halo or unsaturated derivatives of the foregoing, in which G2 is absent or selected from the group consisting of hydrogen, a C1 to C5 hydrocarbon or a bivalent moiety linking G1 and L to form a 5- to 7-membered heterocyclic ring and halo or unsaturated derivatives thereof, in which G3 is selects from the group consisting of hydrogen, methyl and ethyl, in which the benzopyran derivative has the following general structure: in which D is -OCH2CH2N (R3) R4 (R3 and R4 or independently selected from the group consisting of C1 alkyl -C4 or R3, R4 and the nitrogen atom to which they are attached together form a structure selected from the group consisting of pyrrolidino ring, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneiminium, morpholino); wherein R1 and R2 are independently selected from the group consisting of: hydrogen, hydroxyl and a moiety converted in vivo to hydroxyl; wherein G3 is selected from the group consisting of hydrogen, methyl and ethyl; with the proviso that said selective estrogen receptor modulator is other than the compound EM-800 when the disease is breast cancer. |
| priorityDate | 1998-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 503.